Alto Neuroscience

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Wall Street

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ADUS

ANRO

GRND

USPH

ZBIO

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Crude-oil-4-logo

Earnings

Equities

Eurozone

Commodities

Intraday Update

CNSP

CSTM

ENPH

LRHC

VRAX

Nasdaq Down 2%; US Crude Stocks Increase

Biotech

Health Care

Movers

General

Alto Neuroscience&#39;s ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies.

Neuropsychiatry-Focused Alto Neuroscience&#39;s Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform

Alto Neuroscience Inc

Press Releases

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

Alto Neuroscience to Participate in Upcoming Investor Conferences

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

Legal

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Christopher Nixon Cox Named Chairman of High-Trend International Group

HTCO

ALT5 Sigma

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Assertio Holdings

Bioage Labs

Biote

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Journey Medical Corporation - Common Stock

Journey Medical

Ikena Oncology

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nektar Therapeutics

Nutriband

OptiNose

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Cassava Sciences

Scilex Holding

scPharmaceuticals

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Third Harmonic Bio

Veru

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Ventyx Biosciences

Jones Trading

Stifel

Wedbush

Baird

Rodman & Renshaw

Comments

Alto Neuroscience

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga